At the American Association for Cancer Research 100th Annual Meeting 2009 in Denver, National Cancer Institute (NCI) Director John E. Niederhuber, M.D., announced major details, such as funding more grants, development of a platform for personalized cancer care, and an accelerated cancer genetics program, that will move cancer research forward in this new economic environment. [...]
A phase II trial was just completed at the University of Western Australia to investigate changes in bone mineral density (BMD) and osteoporosis in men on intermittent androgen-suppression therapy (IAST) over a period of three years. This trial, conducted at the Faculty of Medicine, University of Western Australia, Crawley, Department of Radiation Oncology, Sir Charles [...]
Our own Alvin Chin, Prostate Cancer Survivor & Advocate, Virginia Prostate Coalition, joins oncologists Howard Scher MD, Donald S. Coffey, PhD, Peter S. Nelson, MD and representatives from research and the Pharma industry for a round table discussion April 23. You can make your voice heard by joining the conference by phone and emailing questions [...]
Under the resources section of the blog I have just added the Memorial Sloan-Kettering Cancer Center prostate nomogram for PSA doubling and PSA velocity. Joel T Nowak MA, MSW
As a follow up to yesterday's news about the positive results announced about Provenge, I have received a number of private emails asking questions about the treatment. I hope that the following will answer many of the questions people might still have about Provenge. • The other name for Provenge is sipuleucel-T. • Provenge is [...]